Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the cancer and leukemia group B

Martin W. Oster; Richard L. Schilsky; David Faraggi; Ann H. Korzun; Michael Perry; Ann Moore; Jagmohan Kalra; William C. Wood; I. Craig Henderson

doi:10.1002/1097-0142(19911015)68:8<1696::AID-CNCR2820680807>3.0.CO;2-B

Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the cancer and leukemia group B

Martin W. Oster, Richard L. Schilsky, David Faraggi, Ann H. Korzun, Michael Perry, Ann Moore, Jagmohan Kalra, William C. Wood, I. Craig Henderson

Research output: Contribution to journal › Article › peer-review

Abstract

Forty‐four women with advanced breast cancer participated in a prospective clinical trial to evaluate the efficacy and toxicity of a regimen consisting of cytosine arabinoside and cisplatin. All patients had previously received chemotherapy. Three patients (7%) responded to therapy with response durations of 153, 160, and 441 days. The median time to disease progression and median survival time in all 44 patients were 2.3 and 5 months, respectively. This regimen had significant toxicity, with most patients experiencing severe or life‐threatening hematologic, renal, or infectious complications. This regimen cannot be recommended for previously treated patients with advanced breast cancer.

Original language	English
Pages (from-to)	1696-1698
Number of pages	3
Journal	Cancer
Volume	68
Issue number	8
DOIs	https://doi.org/10.1002/1097-0142(19911015)68:8<1696::AID-CNCR2820680807>3.0.CO;2-B
State	Published - 15 Oct 1991
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/1097-0142(19911015)68:8<1696::AID-CNCR2820680807>3.0.CO;2-B

Cite this

@article{45c728c691014a37a7101944ff95f242,

title = "Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the cancer and leukemia group B",

abstract = "Forty‐four women with advanced breast cancer participated in a prospective clinical trial to evaluate the efficacy and toxicity of a regimen consisting of cytosine arabinoside and cisplatin. All patients had previously received chemotherapy. Three patients (7\%) responded to therapy with response durations of 153, 160, and 441 days. The median time to disease progression and median survival time in all 44 patients were 2.3 and 5 months, respectively. This regimen had significant toxicity, with most patients experiencing severe or life‐threatening hematologic, renal, or infectious complications. This regimen cannot be recommended for previously treated patients with advanced breast cancer.",

author = "Oster, \{Martin W.\} and Schilsky, \{Richard L.\} and David Faraggi and Korzun, \{Ann H.\} and Michael Perry and Ann Moore and Jagmohan Kalra and Wood, \{William C.\} and \{Craig Henderson\}, I.",

year = "1991",

month = oct,

day = "15",

doi = "10.1002/1097-0142(19911015)68:8<1696::AID-CNCR2820680807>3.0.CO;2-B",

language = "English",

volume = "68",

pages = "1696--1698",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

TY - JOUR

T1 - Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the cancer and leukemia group B

AU - Oster, Martin W.

AU - Schilsky, Richard L.

AU - Faraggi, David

AU - Korzun, Ann H.

AU - Perry, Michael

AU - Moore, Ann

AU - Kalra, Jagmohan

AU - Wood, William C.

AU - Craig Henderson, I.

PY - 1991/10/15

Y1 - 1991/10/15

N2 - Forty‐four women with advanced breast cancer participated in a prospective clinical trial to evaluate the efficacy and toxicity of a regimen consisting of cytosine arabinoside and cisplatin. All patients had previously received chemotherapy. Three patients (7%) responded to therapy with response durations of 153, 160, and 441 days. The median time to disease progression and median survival time in all 44 patients were 2.3 and 5 months, respectively. This regimen had significant toxicity, with most patients experiencing severe or life‐threatening hematologic, renal, or infectious complications. This regimen cannot be recommended for previously treated patients with advanced breast cancer.

AB - Forty‐four women with advanced breast cancer participated in a prospective clinical trial to evaluate the efficacy and toxicity of a regimen consisting of cytosine arabinoside and cisplatin. All patients had previously received chemotherapy. Three patients (7%) responded to therapy with response durations of 153, 160, and 441 days. The median time to disease progression and median survival time in all 44 patients were 2.3 and 5 months, respectively. This regimen had significant toxicity, with most patients experiencing severe or life‐threatening hematologic, renal, or infectious complications. This regimen cannot be recommended for previously treated patients with advanced breast cancer.

UR - https://www.scopus.com/pages/publications/0026345901

U2 - 10.1002/1097-0142(19911015)68:8<1696::AID-CNCR2820680807>3.0.CO;2-B

DO - 10.1002/1097-0142(19911015)68:8<1696::AID-CNCR2820680807>3.0.CO;2-B

M3 - Article

C2 - 1913511

AN - SCOPUS:0026345901

SN - 0008-543X

VL - 68

SP - 1696

EP - 1698

JO - Cancer

JF - Cancer

IS - 8

ER -

Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the cancer and leukemia group B

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this